Latest news with #AdamFriedman
Business Wire
3 days ago
- Business
- Business Wire
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. ('Antares'), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors. Antares is a spin-out of Scorpion Therapeutics, Inc. ('Scorpion'), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company ('Lilly') in March 2025 for up to $2.5 billion in total consideration. Scorpion was founded in 2020 and, in the subsequent five years, raised a total of $420 million in financing, executed partnerships with multiple pharmaceutical companies, and generated six development candidates, three of which are in clinical testing. Antares is led by Scorpion's former executive leadership team and is advancing a pipeline of small molecule assets developed at Scorpion, including programs in precision oncology and other therapeutic areas, as well as programs initiated through Scorpion's 2022 transcription factor collaboration with AstraZeneca. 'We took our name from Antares, the brightest star in the Scorpius constellation, and known as 'the heart of the Scorpion.' We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets,' said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares and former Chief Executive Officer of Scorpion. 'We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.' 'At Omega, we focus on identifying approaches and working with exceptional teams to deliver impactful products to patients,' said Otello Stampacchia, Ph.D., Founder and Managing Director at Omega Funds. 'Antares meets each of these criteria. As one of the founding investors in Scorpion, we have had the opportunity to follow the company's evolution very closely and have been consistently impressed by the breadth of the team's capabilities, as well as their scientific rigor and rapid execution. I look forward to seeing the company's vision advance by delivering differentiated, first-in-class products to treat some of the most important unmet medical needs.' Additionally, Antares announced that Pierre Fabre Laboratories, with whom Scorpion previously partnered to advance two clinical-stage, highly selective next-generation mutant EGFR inhibitors for the treatment of non-small cell lung cancer, has acquired global rights to both programs. Under the terms of the agreement, Pierre Fabre Laboratories will lead the continued clinical development and global commercialization of both programs, and Antares will be eligible to receive regulatory and commercial milestones and tiered royalties. Antares' leadership team Antares is led by the former Scorpion executive team, including leaders with accomplished track records in the biotechnology industry: Adam Friedman, M.D., Ph.D., Chief Executive Officer Natasja Brooijmans, Ph.D., Executive Vice President, Discovery Predictive Sciences Mark Chao, M.D., Ph.D., Chief Medical Officer Andrew Fedder, General Counsel Angel Guzman-Perez, Ph.D., Executive Vice President, Head of Chemistry Erica Jackson, Ph.D., Chief Scientific Officer Darrin Stuart, Ph.D., Chief Development Officer Amanda Valentino, Chief People Officer The company's Board of Directors are industry veterans with company-building expertise, as well as experience pioneering breakthrough medicines: Jeff Albers, J.D., M.B.A., Board Chair at Antares Therapeutics and Venture Partner at Atlas Venture Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School Jean-François Formela, M.D., Partner at Atlas Venture Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares Therapeutics Sir Menelas Pangalos, Ph.D., formerly Executive Vice President of Biopharmaceuticals R&D at AstraZeneca 'After years of investment into its proprietary drug discovery capabilities, the team at Antares has made notable progress to unlock the therapeutic potential of targets long seen as important – but undruggable – like the large class of transcription factors,' said Sir Menelas Pangalos, Ph.D., independent member of the Antares Board. 'I look forward to partnering with the Antares team as they address some of the most complex challenges in science.' 'Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,' said Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center. "This team has demonstrated an ability to break through longstanding limits in medicinal chemistry to advance a pipeline of first-in-class assets, aiming to change the treatment landscape for patients.' About Antares Therapeutics Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares' most advanced program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development. To learn more, visit and follow us on LinkedIn.
Yahoo
3 days ago
- Business
- Yahoo
Antares Therapeutics gains $177m for cancer medicines development
Antares Therapeutics has secured $177m in a Series A financing round for the development of precision medicines to treat cancer and other serious diseases. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026. The round was co-led by Atlas Venture, Omega Funds, Lightspeed Venture Partners, BVF Partners and Cormorant Asset Management. Additional support came from Abingworth, Invus, Tenmile, Vida Ventures, Vinyanshu Ventures and Willett Advisors. Antares Therapeutics CEO Adam Friedman stated: 'We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fuelled by discoveries in drugging previously inaccessible targets. 'We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.' The newly established company is a spin-out from Scorpion Therapeutics, which sold its STX-478 programme to Eli Lilly in March 2025 for $2.5bn. Founded in 2020, Scorpion raised $420m in the next five years while partnering with several pharmaceutical firms and producing six development candidates, three of which are now undergoing clinical trials. Under the guidance of Scorpion's former executive leadership team, Antares aims to progress small-molecule assets developed at Scorpion within precision oncology, among other areas. Pierre Fabre Laboratories has acquired global rights to two clinical-stage mutant epidermal growth factor receptor inhibitors from Scorpion for non-small cell lung cancer treatment. With this deal, Pierre Fabre will oversee their continued clinical development and global commercialisation efforts while Antares stands to gain regulatory milestones as well as tiered royalties. "Antares Therapeutics gains $177m for cancer medicines development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WebMD
4 days ago
- Health
- WebMD
Sunscreen Fears Are Spreading — Here's the Truth
June 10, 2025 — Just as summer begins and people are stocking up on sunscreen, a new report is raising questions about the safety and effectiveness of many brands. But the truth behind those attention - grabbing headlines is more complicated. The research, conducted by a nonprofit advocacy group that verifies sunscreens with its own seal, looked at more than 2,200 sunscreens and found that just 498 met its high bar for safety and effectiveness. While the group, called the Environmental Working Group (EWG), raises valid concerns about certain chemical ingredients, which some studies link to health risks in mice, experts caution that the report leaves out key research findings. 'They used a fraction of the literature out there to determine safety,' said Adam Friedman, MD a dermatologist at The George Washington University School of Medicine & Health Sciences in Washington, D.C. Two JAMA studies cited by the report, for instance, found that various UV filters — the chemicals in sunscreens that absorb or block sunlight — could be detected in people's blood after repeated application, but neither study showed effects on the body, Friedman said. 'The reality is, whether it be human safety or even environmental safety, there are tons of studies showing the safety of the very few organic and mineral filters that we have,' said Friedman. 'Also there's tons of longitudinal data showing that the sunscreens we have, the ingredients we have, can protect against accelerated skin aging and skin cancer.' In the U.S., 1 in 5 people will develop skin cancer by age 70, and 20 people per day die of melanoma, the deadliest form of skin cancer. David Andrews, PhD, the EWG's acting chief science officer, said the sunscreen ratings were based on a 'comprehensive review of the most current, peer-reviewed' science plus data from federal agencies like the FDA and health and safety organizations from around the world. 'We assess ingredients for both health hazards — such as hormone disruption, developmental toxicity, and allergic reactions — and for their efficacy in protecting against UVA and UVB radiation,' said Andrews, noting that the group's standards 'go beyond what is required by [the] FDA.' 'Not all sunscreens are created equal, and it's about making informed choices,' Andrews said. 'We share a common goal with dermatologists: reducing skin cancer risk.' The real takeaway: It's a good opportunity to understand how sunscreens work and how to choose the right one for you. First, What Is SPF? SPF, or sun protection factor, is the level of protection from UVB rays that a product provides. The sun releases a full spectrum of ultraviolet (UV) radiation, a form of energy that's part of the electromagnetic spectrum. UVB is a type of UV radiation, and so is UVA. UVB rays are shorter and have a greater effect on sunburn. They can also damage the skin's DNA, leading to skin cancer. SPF 15 provides over 94% protection, allowing about 6% of UVB rays to reach your skin. SPF 30 provides 97% protection, SPF 50 provides 98% protection, and SPF 100 provides 99% protection. The SPF number indicates protection compared to no sunscreen. For instance, it will take 30 times longer for your skin to burn if you wear the recommended amount of SPF 30, versus wearing no sunscreen. What About UVA? UVA rays are longer and penetrate deeper into the skin, causing skin aging. They also contribute to sunburn, skin cancers, and rashes, said Zakia Rahman, MD, clinical professor of dermatology at Stanford. Broad-spectrum sunscreens protect you against both UVB and — to an extent — UVA rays. However, 'they're not great at UVA,' Friedman said. 'They're sufficient from an FDA perspective, but they're not great. We have very few UVA filters.' What's the Difference Between Mineral and Chemical Sunscreens? 'They work in different ways, but they still achieve the same effect,' said Syril Keena Que, MD, MPH, professor of dermatology at the Indiana University School of Medicine in Indianapolis. Chemical sunscreens contain organic (carbon-containing) UV filters called oxybenzone or avobenzone, which absorb UV radiation, converting it into heat, said Que. Mineral (also known as physical) sunscreens contain UV filters like titanium dioxide or zinc oxide — metal particles that block, reflect, and scatter UV rays. Mineral sunscreens tend to cause fewer allergic reactions and may be better for people with sensitive skin, Que said, such as babies and young children and those with skin conditions like eczema or psoriasis. Hybrid sunscreens use both kinds of filters. When chemical filters absorb UV radiation, their electrons become excited. As they return to normal, they release that energy as heat. But over time, 'they get stuck in that higher level of excitement,' Friedman said, and stop protecting your skin. Combining them with mineral filters takes some of the load off them, Friedman said. 'Minerals can do it all day. They're not going to burn out." Are Sunscreen Ingredients Safe? Several sunscreen ingredients — including oxybenzone and avobenzone — lack enough safety data to be generally recognized as safe and effective (GRASE) by the FDA. Some studies in mice have linked those ingredients to cancer and hormone disruption. That has influenced the EWG's methodology and the results of their latest sunscreen report. 'Our top recommended sunscreens are primarily mineral sunscreens using zinc oxide or titanium dioxide,' said Andrews, of the EWG. In 2019, the FDA determined that these two mineral blockers are the only sunscreen active ingredients that are GRASE. But the GRASE category 'is almost to the detriment' of consumers, Rahman said, 'because a lot of chemical sunscreens work really well.' While endocrine disruption, specifically caused by microplastics, is a "legitimate" concern, "we have to balance that with skin cancer risks." While it's true chemical filters lack enough research to confirm they're safe, there's not enough data to say they're dangerous, either. Friedman pointed to a 2025 study that found six common chemical UV filters, including avobenzone, do not cause cancer. So Why Not Just Use Mineral Sunscreens? While chemical sunscreens are made so your skin absorbs them, mineral sunscreens sit on top of your skin. Both zinc oxide and titanium dioxide are 'very white, so that limits who can use the products,' Rahman said. They can leave a visible white or gray layer, making them less appealing for people of color. Some brands add tinting agents like iron oxide or pigment particles, providing protection against visible light (known to stimulate melanin production), Rahman said. That makes them potentially a good option for those who are prone to pigmentation and dark spots. But even tinted mineral sunscreens can still leave a cast on the skin. "Being a person of color myself and having a lot of patients with pigmentary disorders, it's important for me to talk about the different wavelengths of light and how people can protect themselves," Rahman said. Europe and Asia offer a wider variety of sunscreens for different skin tones, Rahman said, but because European and Asian sunscreens are regulated under a different system (one that classifies them as cosmetics, not drugs), they aren't subject to the same rigorous testing required in the U.S., where sunscreens are regulated by the FDA as over-the-counter drugs. In 2006, the FDA granted approval to products containing Mexoryl SX, an organic compound that protects against UVA and was already being used abroad. But many dermatologists say that consumers need more options. 'We're really advocating for the FDA to approve more products so we have new things available that cover UVA and provide a more broad-spectrum sunscreen in the U.S.," Rahman said. How Is SPF measured? SPF is measured in a lab with human participants, who are doused with the recommended sunscreen amount: 2 milligrams per square centimeter of skin, or about a teaspoon for the face and an ounce (about equal to a shot glass) for the body. They're exposed to UVB light, with and without sunscreen. SPF is determined by how long it takes for the skin to turn red. 'They look at what's called the minimal erythema dose, which tells you how your skin responds and if it's sunburned,' Rahman said. Broad spectrum sunscreens also undergo lab testing using a skin-like substance instead of real skin to determine protection from UVA rays. A spectrophotometer machine helps identify different wavelengths of light and which ones are blocked, Rahman said. Does Lab Testing Reflect How People Really Use SPF? Not really. Most people use between 20% and 50% of the recommended amount. 'When you're using an SPF 50, for example, it may be only equivalent to an SPF 15 or 25, based on how much you're applying,' Que said. Is SPF 100 worth using? 'It does have a benefit only because people are under-applying,' Que said. 'My daily sunscreen probably has SPF 30 or 40, but if I'm going to the beach or getting a lot of sun exposure, then I do like trying to find a higher SPF sunscreen because it does offer a little bit more protection.' To get that protection, you'd also need to reapply at least every two hours if you're sweating or exposed to water, Que said. Wiping away sweat also removes sunscreen from the skin. Water-resistant sunscreens create a hydrophobic film on the skin that repels water, but they still provide only 40 to 80 minutes of water resistance. 'It doesn't mean that the whole time you're swimming, the sunscreen is going to stay on,' Que said. 'Eventually it does wash off too.' The FDA outlawed use of the terms 'sunblock,' 'waterproof,' and 'sweatproof' in 2011 because they may give people a false sense of protection from harmful rays. What's the Bottom Line? Choose products that are SPF 30 or higher, broad spectrum, and water resistant for 80 minutes, Friedman said. Patch-testing samples of different sunscreens can be helpful for finding one that you like. 'The best sunscreen is the one that you're going to use repeatedly,' Friedman said. Que emphasized the importance of daily sunscreen use — at least SPF 30 — on the face, neck, and any exposed areas, such as arms and hands. 'Oftentimes, it's that cumulative sun damage over many years that results in skin cancer,' she said. Use sunscreen sprays in well-ventilated areas to avoid breathing in harmful chemicals, Que said. Spray products may contain benzenes, which are carcinogens. Because benzene isn't added to sunscreen intentionally but can result from the manufacturing process, it's not listed on the label. "There's no way for consumers to identify which sprays might contain trace benzene," Que said. "That's why using sprays in well-ventilated areas and avoiding inhalation is wise." Choosing lotion-based sunscreens can reduce that risk, she said. And don't forget other sun-protective behaviors like seeking shade and wearing broad-brimmed hats, UV protection factor (UPF) clothing, and sunglasses. And try to avoid sun exposure during the middle of the day, when the UV index tends to be highest. Heading outside later in the day offers additional health benefits. 'I am a big proponent of sunset walks,' Rahman said. 'The red light and near-infrared light of the setting sun is great for our mitochondria,' helping our cells to stay healthy.
Yahoo
4 days ago
- Business
- Yahoo
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
– Spin-out of Scorpion Therapeutics, led by former Scorpion Therapeutics management team – – Advancing multiple programs across cancer and other serious diseases; plans to advance first new product candidate into the clinic in 2026 – – Series A financing co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from other leading healthcare funds – BOSTON, June 10, 2025--(BUSINESS WIRE)--Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors. Antares is a spin-out of Scorpion Therapeutics, Inc. ("Scorpion"), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company ("Lilly") in March 2025 for up to $2.5 billion in total consideration. Scorpion was founded in 2020 and, in the subsequent five years, raised a total of $420 million in financing, executed partnerships with multiple pharmaceutical companies, and generated six development candidates, three of which are in clinical testing. Antares is led by Scorpion's former executive leadership team and is advancing a pipeline of small molecule assets developed at Scorpion, including programs in precision oncology and other therapeutic areas, as well as programs initiated through Scorpion's 2022 transcription factor collaboration with AstraZeneca. "We took our name from Antares, the brightest star in the Scorpius constellation, and known as 'the heart of the Scorpion.' We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets," said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares and former Chief Executive Officer of Scorpion. "We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need." "At Omega, we focus on identifying approaches and working with exceptional teams to deliver impactful products to patients," said Otello Stampacchia, Ph.D., Founder and Managing Director at Omega Funds. "Antares meets each of these criteria. As one of the founding investors in Scorpion, we have had the opportunity to follow the company's evolution very closely and have been consistently impressed by the breadth of the team's capabilities, as well as their scientific rigor and rapid execution. I look forward to seeing the company's vision advance by delivering differentiated, first-in-class products to treat some of the most important unmet medical needs." Additionally, Antares announced that Pierre Fabre Laboratories, with whom Scorpion previously partnered to advance two clinical-stage, highly selective next-generation mutant EGFR inhibitors for the treatment of non-small cell lung cancer, has acquired global rights to both programs. Under the terms of the agreement, Pierre Fabre Laboratories will lead the continued clinical development and global commercialization of both programs, and Antares will be eligible to receive regulatory and commercial milestones and tiered royalties. Antares' leadership team Antares is led by the former Scorpion executive team, including leaders with accomplished track records in the biotechnology industry: Adam Friedman, M.D., Ph.D., Chief Executive Officer Natasja Brooijmans, Ph.D., Executive Vice President, Discovery Predictive Sciences Mark Chao, M.D., Ph.D., Chief Medical Officer Andrew Fedder, General Counsel Angel Guzman-Perez, Ph.D., Executive Vice President, Head of Chemistry Erica Jackson, Ph.D., Chief Scientific Officer Darrin Stuart, Ph.D., Chief Development Officer Amanda Valentino, Chief People Officer The company's Board of Directors are industry veterans with company-building expertise, as well as experience pioneering breakthrough medicines: Jeff Albers, J.D., M.B.A., Board Chair at Antares Therapeutics and Venture Partner at Atlas Venture Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School Jean-François Formela, M.D., Partner at Atlas Venture Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares Therapeutics Sir Menelas Pangalos, Ph.D., formerly Executive Vice President of Biopharmaceuticals R&D at AstraZeneca "After years of investment into its proprietary drug discovery capabilities, the team at Antares has made notable progress to unlock the therapeutic potential of targets long seen as important – but undruggable – like the large class of transcription factors," said Sir Menelas Pangalos, Ph.D., independent member of the Antares Board. "I look forward to partnering with the Antares team as they address some of the most complex challenges in science." "Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development," said Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center. "This team has demonstrated an ability to break through longstanding limits in medicinal chemistry to advance a pipeline of first-in-class assets, aiming to change the treatment landscape for patients." About Antares Therapeutics Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares' most advanced program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development. To learn more, visit and follow us on LinkedIn. View source version on Contacts Media:Emily Investor:Danielle DudgeonPrecision Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
22-05-2025
- Health
- Associated Press
MINO Labs Publishes First-Ever Human Clinical Trial Demonstrating Protective Benefits of CBD Cream Against UVA-Induced Skin Damage--Offering New Hope for Fighting Skin Cancer and Photoaging
New science and skincare innovation, CielementsMD® DNA Defense Daily Cream, works with sunscreen to prevent photoaging and lower skin cancer risk—with clinically-proven results. NEW YORK, May 22, 2025 /PRNewswire/ -- MINO Labs, LLC ('MINO Labs'), a privately held specialty pharmaceutical company, is proud to announce the publication of a groundbreaking clinical study in the Journal of the American Academy of Dermatology (JAAD), highlighting the protective benefits of its patented CannaXR™ (extended release) cannabidiol (CBD) cream: DNA Defense Daily Cream. As May marks Skin Cancer Awareness Month and 'Don't Fry Day' falls on May 23, this scientific milestone establishes a new category of sun protection at a crucial time of year for sun safety awareness—offering fresh hope in the fight against skin aging and sun-induced skin cancers. The peer-reviewed study is the first-ever in-human clinical trial to demonstrate that a CBD-based topical can reduce Ultraviolet A (UVA)-induced DNA damage at the cellular level, preventing both nuclear and mitochondrial DNA mutations associated with accelerated skin aging and skin cancer. 'CBD has a volume of supporting evidence in the literature for enumerable skin benefits, however the translation to the bottle in your hand has been limited due to its ability to actually get into the skin. The innovative delivery system used in this product, Z-pods™, fills that gap and now allows us to take full advantage of the incredible potential CBD has to offer,' said Dr. Adam Friedman, Professor and Chair of Dermatology at The George Washington University School of Medicine and Health Sciences and co-inventor of the Z-pod™ technology. The full study, titled 'Topical Nanoencapsulated Cannabidiol Cream as an Innovative Strategy Combating UVA-Induced Nuclear and Mitochondrial DNA Injury: A Pilot Randomized Clinical Study,' is available here: JAAD. Key Findings from Clinical Trial (NCT05279495): 'This landmark study represents a major advance in dermatological protection and anti-aging science,' said Dr. Brian Berman, MD, PhD, principal investigator and past Vice President of the American Academy of Dermatology. 'With skin cancer still the most diagnosed cancer in the U.S., solutions like CannaXR™ that demonstrate molecular protection are a vital step forward.' According to the U.S. Centers for Disease Control and Prevention, more than 6.1 million U.S. adults are treated annually for basal and squamous cell carcinoma, costing over $8.9 billion. UVA exposure plays a major role in this, accelerating both visible aging and DNA damage that can lead to cancer. CannaXR™: Science Meets Skincare in the Fight Against Sun Damage Developed by MINO Labs, CannaXR™ combines advanced nanotechnology and cannabidiol in a novel extended-release cream that may offer a new kind of topical protection—complementing sunscreen, but focused on reducing internal cellular damage 'Innovative drug delivery systems are key factors on effectiveness of each product' mentioned Manuel Cosme Odabachian, CEO of MINO Labs. As we recognize Skin Cancer Awareness Month, MINO Labs is committed to driving awareness and offering evidence-based tools to help individuals better protect their skin and long-term health. About MINO Labs MINO Labs is a specialty pharmaceutical company leveraging two decades of dermatologic innovation to develop next-generation wellness and protective therapies. With a growing pipeline of nanotechnology-based products, MINO Labs is poised to transform how we protect and preserve skin health. Learn more: Contact: Jennifer Fisherman-Ruff [email protected] Carina Bonasera [email protected] Emily Tindol [email protected] View original content to download multimedia: SOURCE MINO Labs
